Home » Stocks » Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (BIO)

Class A Shares
Stock Price: $524.13 USD -1.09 (-0.21%)
Updated Aug 7, 2020 4:03 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 15.56B
Revenue (ttm) 2.29B
Net Income (ttm) 1.95B
Shares Out 24.59M
EPS (ttm) 64.50
PE Ratio 8.13
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $524.13
Previous Close $525.22
Change ($) -1.09
Change (%) -0.21%
Day's Open 524.64
Day's Range 518.50 - 527.63
Day's Volume 181,442
52-Week Range 309.38 - 540.06

More Stats

Market Cap 15.56B
Enterprise Value 15.16B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.59M
Float 21.21M
EPS (basic) 65.39
EPS (diluted) 64.50
FCF / Share 10.87
Dividend n/a
Dividend Yield n/a
Earnings Yield 12.31%
FCF Yield 2.07%
Payout Ratio n/a
Shares Short 576,427
Short Ratio 1.42
Short % of Float 2.70%
Beta 1.11
PE Ratio 8.13
Forward PE n/a
P/FCF Ratio 48.28
PS Ratio 6.78
PB Ratio 2.13
Revenue 2.29B
Operating Income 242.78M
Net Income 1.95B
Free Cash Flow 322.16M
Net Cash 391.59M
Net Cash / Share 13.19
Gross Margin 55.00%
Operating Margin 10.59%
Profit Margin 84.90%
FCF Margin 14.05%
ROA 1.92%
ROE 30.33%
ROIC 34.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$603.75*
(15.19% upside)
Low
585
Current: $524.13
High
625
Target: 603.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2,3122,2892,1602,0682,0192,1752,1332,0692,0741,927
Revenue Growth0.97%5.98%4.45%2.41%-7.15%1.99%3.07%-0.21%7.6%-
Gross Profit1,2571,2231,1881,1381,1221,1791,1781,1551,1791,091
Operating Income230-10311955.72167150169264305284
Net Income1,75936612226.0010988.8577.79165179185
Shares Outstanding29.8429.8429.6629.4429.1928.8828.5928.2928.0327.67
Earnings Per Share58.2712.104.070.883.713.052.695.786.296.59
EPS Growth381.57%197.3%362.5%-76.28%21.64%13.38%-53.46%-8.11%-4.55%-
Operating Cash Flow458285104216186273169266263226
Capital Expenditures-98.40-126-111-141-112-121-105-137-103-87.26
Free Cash Flow359160-7.1175.0374.2915363.69130160139
Cash & Equivalents1,1208507618447906986099218131,032
Total Debt651439435435434436437734733964
Net Cash / Debt46941132640935626217218780.6067.33
Assets8,0095,6114,2733,8513,7103,3413,3893,4443,0973,063
Liabilities2,2541,5911,3431,2711,2191,1561,2021,4281,3521,522
Book Value5,7554,0202,9302,5792,4912,1852,1872,0151,7441,537
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bio-Rad Laboratories, Inc.
Country United States
Employees 8,000
CEO Norman D. Schwartz

Stock Information

Ticker Symbol BIO
Stock Exchange New York Stock Exchange
Share Class Class A Shares
Sector Healthcare
Industry Medical Devices
Unique Identifier NYSE: BIO

Description

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.